Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Orthocell Ltd ( (AU:OCC) ) is now available.
Orthocell Limited reported a record quarterly revenue of $3.0 million, marking the sixth consecutive quarter of growth, driven by the increasing market penetration of its nerve repair product, Remplir, in Australia and Singapore. The company is strategically expanding its commercial operations in the US and Canada, with early successes in the US market and plans for further growth in North America. The use of Remplir in nerve-sparing prostate cancer surgeries presents a significant opportunity to expand its market reach, while recent leadership appointments are expected to strengthen its operational capabilities.
The most recent analyst rating on (AU:OCC) stock is a Hold with a A$1.50 price target. To see the full list of analyst forecasts on Orthocell Ltd stock, see the AU:OCC Stock Forecast page.
More about Orthocell Ltd
Orthocell Limited is a regenerative medicine company focused on developing and commercializing innovative medical devices. The company primarily operates in the nerve repair market, with its flagship product, Remplir, gaining significant traction in Australia, Singapore, and expanding into the US and Canadian markets.
Average Trading Volume: 573,334
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$359.4M
Learn more about OCC stock on TipRanks’ Stock Analysis page.